ARCUTIS BIOTHERAPEUTICS INC
NASDAQ: ARQT (Arcutis Biotherapeutics, Inc.)
Last update: 15 hours ago26.36
-0.81 (-2.98%)
| Previous Close | 27.17 |
| Volume | 1,290,169 |
| Avg. Volume (3M) | 2,594,581 |
| Market Cap | 3,333,354,752 |
| Price / Earnings (TTM) | 119.82 |
| Price / Earnings (Forward) | 31.87 |
| Price / Sales | 7.28 |
| Price / Book | 14.26 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2026 |
| Profit Margin | 5.88% |
| Operating Margin (TTM) | 6.91% |
| Diluted EPS (TTM) | 0.220 |
| Quarterly Revenue Growth (YOY) | 45.10% |
| Quarterly Earnings Growth (YOY) | 18.80% |
| Total Debt/Equity (MRQ) | 50.75% |
| Current Ratio (MRQ) | 2.92 |
| Operating Cash Flow (TTM) | 59.96 M |
| Levered Free Cash Flow (TTM) | 32.62 M |
| Return on Assets (TTM) | 4.91% |
| Return on Equity (TTM) | 14.88% |
News Mood
-
Arcutis Biotherapeutics Inc (ARQT) (Q3 2026) Earnings Call Highlights: Revenue Surges 45% to ...
07 Nov, 5:08PM
-
Arcutis Biotherapeutics Q3 Earnings Call Highlights
04 Nov, 6:14PM
-
Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update
04 Nov, 3:00PM
AIStockmoo Score
| Value 30% | -3.4 |
| The price implies earnings growth of 37.8% a year; the business can fund about 14.9% a year. info | |
| Low debt. Strong profitability. Ample short-term liquidity. Positive cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Valuation History info | NA |
| Return on Capital info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | 0.8 |
| No clear trend over the past year. Somewhat below its 52-week high. info | |
| No clear trend: the price is moving around its moving averages. It is close to them. info | |
| From our AI technical analysis of the chart. info | NA |
| Sentiment 20% | 0.3 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mostly positive. info | |
| Holdings' Sentiment info | NA |
| Smart Money 20% | 3.2 |
| Institutions net +17.12% of shares in their latest 13F filings: 196 holders increased, 118 decreased (quarter to 30 Sep 2026). info | |
| Short interest +9.7% from 31 Aug to 30 Oct 2026, 7.6 days to cover (FINRA). info | |
| Insider Activity info | NA |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars disagree, so the score is softened. | |
| Not in score | |
| Priced high for its earnings growth. info | |
| Earnings per share have gone up and down. Made a loss in recent years. info | |
| Recent bullish reversal pattern: Inverted hammer. info | |
| Near its medium-term trend line. info | |
| Price is near its 52-week average. Up over 5 years. info | |
| Short-term momentum falling. info | |
| Price is near support. Levels trending up. info | |
| Final Score | -0.07 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Arcutis Biotherapeutics, Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| ARQT | 3 B | - | 119.82 | 14.26 | -0.1 |
| SYRE | 9 B | - | - | 10.08 | 1.1 |
| MDGL | 9 B | - | - | 14.74 | -0.4 |
| CORT | 7 B | - | 47.78 | 8.89 | -1.5 |
| DFTX | 5 B | - | - | 4.54 | 0.0 |
| FOLD | 5 B | - | - | - | 0.0 |
Select this tab to load the latest available analysis.
|
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.68% |
| % Held by Institutions | 122.12% |
No data within this time range.
Institutions
Institutional ownership: 125.70%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 196 | 30,954,232 |
| Decreased | 118 | 10,907,991 |
| New | 67 | 6,724,646 |
| Sold out | 43 | 5,202,713 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 18,157,145 | 7.6 |
| 15 Oct 2026 | 20,485,453 | 9.8 |
| 30 Sep 2026 | 21,688,918 | 4.8 |
| 15 Sep 2026 | 18,458,091 | 8.5 |
| 31 Aug 2026 | 16,557,048 | 9.4 |
| 14 Aug 2026 | 14,717,905 | 8.0 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 13 Nov 2026 | Yahoo Finance |
Arcutis Biotherapeutics (ARQT) Stock Looks Expensive Despite Its Huge Three Year Run
Arcutis Biotherapeutics has seen its share price move sharply in recent years, helped by growing attention on its dermatology franchise and new clinical milestones. With the stock now reflecting that shift, the key issue for you as an investor is whether the current valuation is still supported by… |
| 13 Nov 2026 | Yahoo Finance |
Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Meeting
New INTEGUMENT-INFANT trial results demonstrate improvements in itch, reductions in symptoms, and improvements in quality of life for infants with atopic dermatitis and their familiesFindings further support investigational ZORYVE cream 0.05% to help address unmet needs in infants aged 3 to… |
| 07 Nov 2026 | Yahoo Finance |
Arcutis Biotherapeutics Inc (ARQT) (Q3 2026) Earnings Call Highlights: Revenue Surges 45% to ...
Arcutis Biotherapeutics Inc (ARQT) posted strong Q3 2026 net product revenue growth, lifted full-year guidance to $535-$545 million, and outlined multiple pipeline catalysts despite elevated expenses. |
| 06 Nov 2026 | Yahoo Finance |
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 58,500 restricted stock units… |
| 06 Nov 2026 | Yahoo Finance |
Arcutis Biotherapeutics (ARQT) Raised 2026 Sales Guidance, Is The Upside Already Priced In?
Arcutis Biotherapeutics (ARQT) drew investor attention after reporting third quarter 2026 earnings, with net product revenue for ZORYVE up 45% year over year and full year sales guidance nudged higher. The reaction in Arcutis Biotherapeutics’ share price has been sharp, with the stock falling about… |
| 05 Nov 2026 | Yahoo Finance |
Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?
Biotech stocks offered a mixed third-quarter bag on Thursday, with Arcutis reversing and BeOne Medicines surging deeper into its buy zone. |
| 05 Nov 2026 | Yahoo Finance |
Arcutis Biotherapeutics, Inc. Q3 2026 Earnings Call Summary
Moby summary of Arcutis Biotherapeutics, Inc.'s Q3 2026 earnings call… |
| 05 Nov 2026 | Yahoo Finance |
Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis
New INTEGUMENT-3 study to evaluate efficacy, safety, and tolerability of investigational ZORYVE® cream 0.3% in individuals with moderate to severe atopic dermatitisStudy aims to expand once-daily ZORYVE cream treatment to individuals with moderate to severe atopic dermatitisBuilds on existing… |
| 04 Nov 2026 | Yahoo Finance |
Arcutis Biotherapeutics Q3 Earnings Call Highlights
Arcutis Biotherapeutics (NASDAQ:ARQT) raised its full-year 2026 net revenue guidance after third-quarter sales of its ZORYVE skin treatments rose 45% from a year earlier, driven primarily by increased patient demand. The company reported $143.9 million in third-quarter net product revenue, up 11% f… |
| 04 Nov 2026 | Yahoo Finance |
Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of -64.71% and +1.61%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 04 Nov 2026 | Yahoo Finance |
Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update
Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q3 revenues of $143.9 million, +45% versus Q3 of 2025, and +11% versus Q2 of 2026, driven by strong demand growthRaised 2026 full-year net product sales guidance to $535 million–$545 millionPartnered with World Champion gymnast… |
| 29 Oct 2026 | Yahoo Finance |
Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
| 28 Oct 2026 | Yahoo Finance |
Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth
Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
| 28 Oct 2026 | Yahoo Finance |
Arcutis Appoints Rob Scott, MD to Board of Directors
WESTLAKE VILLAGE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-dermatology, today announced that Rob Scott, MD has been appointed to the Arcutis Board of… |
| 27 Oct 2026 | Yahoo Finance |
Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
WESTLAKE VILLAGE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the Guggenheim 3rd… |
| 21 Oct 2026 | Yahoo Finance |
Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026
WESTLAKE VILLAGE, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its third quarter 2026 financial results and… |
| 19 Oct 2026 | Yahoo Finance |
Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares Climb
Arcutis Biotherapeutics (NASDAQ:ARQT) saw its share price jump by 10.65 percent to close at $31.89 apiece after earning a bullish outlook and a double-digit price target hike from an analyst. In its market note, investment firm Guggenheim upgraded its stock target by 15.8 percent to $44 from $38… |
| 19 Oct 2026 | Yahoo Finance |
Clinical Data Update Could Shape The Case For Arcutis Biotherapeutics Stock
Arcutis Biotherapeutics reported past conference data on its ZORYVE portfolio, including Phase 2 INTEGUMENT-INFANT results in atopic dermatitis and multiple analyses across creams and foams for plaque psoriasis and seborrheic dermatitis, covering different strengths, formulations, and approved age… |
| 19 Oct 2026 | Yahoo Finance |
Arcutis Soars 12% as Guggenheim Lifts Target to $44 on “Growing Conviction” in 2027
Key TakeawaysArcutis shares rose 12% after Guggenheim raised its price target to $44 from $38 and kept its Buy rating, citing “growing conviction” about 2027. It’s the second bullish call in a week, after Cantor Fitzgerald started coverage on Thursday with an Overweight rating and a $48 target. |
| 12 Oct 2026 | Yahoo Finance |
2 Stocks That Could Soar in Q4
These growth companies offer investors the potential for near-term upside from fourth-quarter catalysts and long-term growth from realizing value in their pipelines. |
| Show more | ||
Recent Signals candle patterns and EMA crosses
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |